Patients with head and neck cancer may need more intensive pain management to maintain daily functioning: a multi-center study

Cho, Shih‐Feng; Rau, Kun Ming; Shao, Yu‐Yun; Yen, Chia Jui; Wu, Ming; Chen, Jen Shi; Chang, Cheng; Yeh, Shih-Peng; Chiou, Tzeon Jye; Hsieh, Ruey Kuen; Lee, Ming Yang; Sung, Yung Chuan; Lee, Kuan Der; Lai, Pang Yu; Yu, Ming; Hwang, Wen Li; Liu, Ta Chih

doi:10.1007/s00520-018-4404-x

Cited by 10 publications

(9 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Opioids are commonly used for short‐ and long‐term cancer pain management in HNC 15‐17 . Exposure to opioids, in combination with other risk factors that are common in survivors of HNC (eg, history of addiction, anxiety, and distress) may all contribute to opioid misuse.…”

Section: Introductionmentioning

confidence: 99%

“…[12][13][14] Opioids are commonly used for short-and long-term cancer pain management in HNC. [15][16][17] Exposure to opioids, in combination with other risk factors that are common in survivors of HNC (eg, history of addiction, anxiety, and distress) may all contribute to opioid misuse. Other opioidrelated harms, such as fatigue, xerostomia, and endocrinopathies, may also be especially damaging in the context of treatment-related toxicities and an older survivor population, who may be susceptible to polypharmacy, falls, and fractures.…”

Section: Introductionmentioning

confidence: 99%

“…[18][19][20] There is limited evidence characterizing the risk of opioid dependence in the years after treatment for HNC. 17,21,22 Single institution retrospective reviews have found that 7% to 15% of patients treated for HNC continued to use opioids at >1 year out from curative intent radiation therapy or surgery. 23,24 These studies do not elucidate whether HNC survivors actually have higher rates of chronic opioid use than people without cancer.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Trends in chronic opioid therapy among survivors of head and neck cancer

et al. 2020

View full text Add to dashboard Cite

Background: Survivors of head and neck cancer (HNC) have increased risk of opioid misuse. Methods: Using Surveillance, Epidemiology and End-Results-Medicare data, we matched adults ≥66 years diagnosed with HNC 2008-2015 with cancer-free controls. We computed odds ratios (OR) for receipt of chronic opioid therapy (COT, claims for ≥90 consecutive days) for HNC survivors compared to controls each year after matching through 2016.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Trends in chronic opioid therapy among survivors of head and neck cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Chronic pain is a severe condition that considerably interferes with daily functioning [1], and the estimated prevalence of chronic pain ranges from 8.7% to 64.4% [2,3]. Neuropathic pain (NP) is a prominent type of chronic pain.…”

Section: Introductionmentioning

confidence: 99%

Transcranial Ultrasound Stimulation of the Anterior Cingulate Cortex Reduces Neuropathic Pain in Mice

Feng

Niu

Meng

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Focused ultrasound (FUS) is a potential tool for treating chronic pain by modulating the central nervous system. Herein, we aimed to determine whether transcranial FUS stimulation of the anterior cingulate cortex (ACC) effectively improved chronic pain in the chronic compress injury mice model at different stages of neuropathic pain. The mechanical threshold of pain was recorded in the nociceptive tests. We found FUS stimulation elevated the mechanical threshold of pain in both short-term ( p < 0.01 ) and long-term ( p < 0.05 ) experiments. Furthermore, we determined protein expression differences in ACC between the control group, the intervention group, and the Sham group to analyze the underlying mechanism of FUS stimulation in improving neuropathic pain. Additionally, the results showed FUS stimulation led to alterations in differential proteins in long-term experiments, including cellular processes, cellular signaling, and information storage and processing. Our findings indicate FUS may effectively alleviate mechanical neuropathic pain via the ACC’s stimulation, especially in the chronic state.

show abstract

“…Head and neck squamous cell carcinoma (HNSCC) frequently invades the facial bones [ 1 ], and this invasion promotes HNSCC bone pain (HNSCC-BP) [ 2 ]. Cancer pain contributes to increased mortality and is a prognostic factor of poor clinical outcomes [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Lactate Transporter Monocarboxylate Transporter 4 Induces Bone Pain in Head and Neck Squamous Cell Carcinoma

Hasegawa

Okui

Shimo

et al. 2018

IJMS

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) poses a significant challenge clinically, as it can invade facial bones and cause bone pain that is undertreated and poorly understood. Here we studied HNSCC bone pain (HNSCC-BP) in an intratibial mouse xenograft model that uses a human HNSCC cell line (SAS cells). These mice develop HNSCC-BP associated with an upregulation of phosphorylated ERK1/2 (pERK1/2), which is a molecular indicator of neuron excitation in the dorsal root ganglia (DRGs) of sensory nerve cell bodies. Our experiments demonstrated that the inhibition of monocarboxylate transporter 4 (MCT4) by short hairpin (shRNA) transduction suppressed the HNSCC-BP, the lactate level in bone marrow, and the pERK1/2 expression in DRG. The sensory nerves also expressed increased levels of the acid-sensing receptor TRPV1. DRG neurons co-cultured with SAS cells showed increased neurite outgrowth, and were inhibited by MCT4 silencing with shRNA. Collectively, our results show that HNSCC induced an acidic bone microenvironment that evokes HNSCC-BP via MCT4 expression.

show abstract

Patients with head and neck cancer may need more intensive pain management to maintain daily functioning: a multi-center study

Abstract: The HNC patients may need more intensive pain management to achieve optimal pain control and maintain daily functioning.

Cited by 10 publications

References 38 publications

Trends in chronic opioid therapy among survivors of head and neck cancer

Trends in chronic opioid therapy among survivors of head and neck cancer

Transcranial Ultrasound Stimulation of the Anterior Cingulate Cortex Reduces Neuropathic Pain in Mice

Lactate Transporter Monocarboxylate Transporter 4 Induces Bone Pain in Head and Neck Squamous Cell Carcinoma

Contact Info

Product

Resources

About